Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Samuel David Rabkin, PH.D.

TitleThomas A. Pappas Professor of Neurosciences
InstitutionMassachusetts General Hospital
DepartmentNeurosurgery
AddressMassachusetts General Hospital
Brain Tumor Research Ctr, Simches, CPZN-3800
185 Cambridge St
Boston MA 02114
Phone617/726-6817
Fax617/643-3422

 Mentoring 
 current student opportunities
Available: 05/01/12, Expires: 09/01/14

We are isolating glioblastoma stem cells from patient specimens and characterizing their biology and susceptibility to novel therapeutics. Oncolytic herpes simplex viruses are genetically mutated viruses that replicate selectively in cancer cells and not normal cells, and are being developed to treat glioblastoma patients.

Available: 09/03/12, Expires: 08/29/14

Volunteer research opportunities for medical students, preferably with some laboratory-based research experience, in the Brain Tumor Research Center, Simches Research Building, MGH. Students will learn a technique related to on-going studies and perform experiments under the supervision of experienced laboratory members. Our laboratory focuses on the use of oncolytic herpes simplex virus (oHSV) vectors for cancer therapy. A number of different vector strategies are being developed: (i) oHSV vectors mutated in different viral genes to target the cancer cell phenotype due to physiologic/signaling pathway differences with 'normal' cells; (ii) recombinant oHSV vectors expressing therapeutic transgenes; and (iii) transcriptionally-regulated oHSV vectors that are targeted by cancer-specific gene expression. These vectors are characterized in a range of tumor models; human tumor xenografts in nude mice, mouse tumors in syngeneic mice, cancer stem cells, and transgenic mouse tumor models. We are exploring a number of therapeutic strategies: (i) oHSV in combination with chemotherapeutics or other compounds with synergistic interactions; (ii) targeting the tumor microenvironment using 'armed' oHSV; and (iii) immunotherapy approaches, including ex vivo activated dendritic cells.

 completed student projects
Infection Study of Human Neural Stem Cells with Oncolytic HSV
Summer, 04/02/07 - 08/03/07

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):12006-11.
    View in: PubMed
  2. Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL. Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models. Neoplasia. 2013 Jun; 15(6):591-9.
    View in: PubMed
  3. Rheinbay E, SuvĂ  ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE. An aberrant transcription factor network essential for wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013 May 30; 3(5):1567-79.
    View in: PubMed
  4. Murphy AM, Rabkin SD. Current status of gene therapy for brain tumors. Transl Res. 2013 Apr; 161(4):339-54.
    View in: PubMed
  5. Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther. 2013 Jan; 20(1):17-24.
    View in: PubMed
  6. Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012 Sep; 71(3):741-8; discussion 748.
    View in: PubMed
  7. Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013 Jan; 21(1):68-77.
    View in: PubMed
  8. Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin SD, Liu R. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther. 2012 Oct; 19(10):707-14.
    View in: PubMed
  9. Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med. 2012 Apr; 1(4):322-32.
    View in: PubMed
  10. Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SD. Effect of ?34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol. 2012 Apr; 86(8):4420-31.
    View in: PubMed
  11. Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012 Jan 4; 104(1):42-55.
    View in: PubMed
  12. Wang J, Hu P, Zeng M, Rabkin SD, Liu R. Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol. 2012 Mar; 40(3):757-63.
    View in: PubMed
  13. Wakimoto H, Mohapatra G, Kanai R, Curry WT, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, Martuza RL, Rabkin SD. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012 Feb; 14(2):132-44.
    View in: PubMed
  14. Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011 Dec 1; 17(23):7383-93.
    View in: PubMed
  15. Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther. 2012 Jan; 20(1):37-45.
    View in: PubMed
  16. Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, Mautner VF, Rabkin SD, Demestre M. Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS One. 2011; 6(6):e21099.
    View in: PubMed
  17. Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G. Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clin Cancer Res. 2011 Jul 1; 17(13):4484-93.
    View in: PubMed
  18. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011 Jun 1; 17(11):3686-96.
    View in: PubMed
  19. Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res. 2010 May 15; 70(10):3890-5.
    View in: PubMed
  20. Kanai R, Wakimoto H, Cheema T, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol. 2010 Apr; 6(4):619-34.
    View in: PubMed
  21. Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther. 2010 Jun; 17(6):805-10.
    View in: PubMed
  22. Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther. 2009 Dec; 16(12):1477-82.
    View in: PubMed
  23. Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H, Rabkin SD, Gao G, Sena-Esteves M. Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol. 2010 Feb; 96(3):337-47.
    View in: PubMed
  24. Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, Pikarsky E, Rabkin SD, Panet A, Zamir G. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther. 2009 Jul; 16(7):905-15.
    View in: PubMed
  25. Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81.
    View in: PubMed
  26. Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther. 2009 Jul; 16(7):551-60.
    View in: PubMed
  27. Farrell CJ, Zaupa C, Barnard Z, Maley J, Martuza RL, Rabkin SD, Curry WT. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008 Dec 1; 14(23):7711-6.
    View in: PubMed
  28. Farassati F, Pan W, Yamoutpour F, Henke S, Piedra M, Frahm S, Al-Tawil S, Mangrum WI, Parada LF, Rabkin SD, Martuza RL, Kurtz A. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol. 2008 Dec; 173(6):1861-72.
    View in: PubMed
  29. Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther. 2009 Jan; 17(1):51-6.
    View in: PubMed
  30. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther. 2008 Jun; 16(6):1041-7.
    View in: PubMed
  31. Zaupa, CM, Farrell, CJ, Martuza, RL, Rabkin SD. Induction of Anti-Tumor Immunity to Murine Neuroblastoma by Flt3-Ligand Generated-Dendritic Cells Loaded with Oncolytic Herpes Simplex Virus-Infected Cells. Mol Ther. 2008; 16:S64.
  32. Liu TC, Wakimoto H, Martuza RL, Rabkin SD. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res. 2007 Oct 1; 13(19):5897-902.
    View in: PubMed
  33. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007 Oct 1; 67(19):9371-9.
    View in: PubMed
  34. Jeyaretna DS, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurg Focus. 2007; 22(6):E4.
    View in: PubMed
  35. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 2007 May; 14(5):460-7.
    View in: PubMed
  36. Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 2007 Jan 15; 67(2):440-4.
    View in: PubMed
  37. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res. 2006 Nov 15; 12(22):6791-9.
    View in: PubMed
  38. Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res. 2006 Oct 15; 66(20):10127-35.
    View in: PubMed
  39. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther. 2006 Dec; 14(6):789-97.
    View in: PubMed
  40. Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol. 2006; 6:40.
    View in: PubMed
  41. Todo T, Rabkin SD, Martuza RL, inventors. The use of soluble costimulatory factor for tumor immuno-gene therapy. 2006.
  42. Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res. 2006 May 1; 12(9):2919-27.
    View in: PubMed
  43. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 2006 Mar; 13(3):253-65.
    View in: PubMed
  44. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst. 2006 Jan 4; 98(1):38-50.
    View in: PubMed
  45. Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther. 2006 Jan; 17(1):20-30.
    View in: PubMed
  46. Aghi M, Rabkin S, Martuza RL. Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clin Neurosurg. 2006; 53:65-76.
    View in: PubMed
  47. Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res. 2005 Nov 1; 11(21):7886-90.
    View in: PubMed
  48. Aghi M, Rabkin S. Viral vectors as therapeutic agents for glioblastoma. Curr Opin Mol Ther. 2005 Oct; 7(5):419-30.
    View in: PubMed
  49. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 2005 Apr; 12(8):647-54.
    View in: PubMed
  50. Liu RB, Rabkin SD. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J (Engl). 2005 Feb 20; 118(4):307-12.
    View in: PubMed
  51. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 2005 Feb 15; 65(4):1532-40.
    View in: PubMed
  52. Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin SD, Smith Q, Stevens GH, Neuwelt EA. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):421-8.
    View in: PubMed
  53. Martuza RL, Rabkin SD, Miyatake S-I, inventors. Tissue or cell-specific herpes simplex virus replication. 2004.
  54. Martuza RL, Rabkin SD, Mineta T, inventors. Replication-competent herpes simplex virus mediates destruction of neoplastic cells. 2004.
  55. Todo T, Rabkin SD. Development of oncolytic replication-competent herpes simplex virus vectors. The G207 paradigm. Curiel DT, Douglas JT. editors. Cancer Gene Therapy. 2004; 199-210.
  56. Jasmin L, Rabkin SD, Granato A, Boudah A, Ohara PT. Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex. Nature. 2003 Jul 17; 424(6946):316-20.
    View in: PubMed
  57. Curry WT, Martuza RL, Rabkin SD. G207 infection of dendritic cells: effects on maturation and generation of antitumor immunity. Abs Cong Neurol Surg. 2003; 53:753.
  58. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002 Dec; 9(12):967-78.
    View in: PubMed
  59. Johnson P, Martuza R, Rabkin SD, Todo T, inventors. Viral vectors and their use in therapeutic methods. 2002.
  60. Rabkin SD, Toda M, Martuza RL, inventors. Use of herpes vectors for tumor therapy. 2002.
  61. Todo T, Ebright MI, Fong Y, Rabkin SD. Oncolytic herpes simplex virus (G207) therapy: from basic to clinical. Maruta H. editor. Tumor suppressing viruses, genes, and drugs. 2002; 45-76.
  62. Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia. 2001 Sep-Oct; 3(5):451-6.
    View in: PubMed
  63. Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther. 2001 May 20; 12(8):999-1010.
    View in: PubMed
  64. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001 May 22; 98(11):6396-401.
    View in: PubMed
  65. Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A, Chalavi A. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol. 2001 May; 169(1):64-71.
    View in: PubMed
  66. Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, Rabkin SD. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. 2001 Apr 1; 61(7):3009-15.
    View in: PubMed
  67. Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 2001 Feb; 8(4):332-9.
    View in: PubMed
  68. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001 Jan 1; 61(1):153-61.
    View in: PubMed
  69. Rabkin SD, Moulding HD. Defective intracellular protein trafficking of L1 CAM clinical mutants R184Q and D598N. Abs. Soc. Neurosci. 2001.
  70. Rabkin SD, Hernaiz Driever P. Replication-competent herpes simplex virus vectors for cancer therapy. Rabkin SD, Hernaiz Driever P. editors. Replication-competent viruses for cancer therapy. 2001; 22:1-45.
  71. Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther. 2000 Dec; 2(6):588-95.
    View in: PubMed
  72. Martuza R., Rabkin SD, Mineta T, inventors. Replication-competent herpes simplex virus mediates destruction of neoplastic cells. 2000.
  73. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000 Oct; 2(4):324-9.
    View in: PubMed
  74. Jasmin L, Janni G, Ohara PT, Rabkin SD. CNS induced neurogenic cystitis is associated with bladder mast cell degranulation in the rat. J Urol. 2000 Sep; 164(3 Pt 1):852-5.
    View in: PubMed
  75. Moulding HD, Martuza RL, Rabkin SD. Clinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression. J Neurosci. 2000 Aug 1; 20(15):5696-702.
    View in: PubMed
  76. Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 2000 Jun; 7(6):939-46.
    View in: PubMed
  77. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000 May; 7(10):867-74.
    View in: PubMed
  78. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol. 2000 Apr; 74(8):3832-41.
    View in: PubMed
  79. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 1999 Nov 20; 10(17):2741-55.
    View in: PubMed
  80. Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther. 1999 Nov 20; 10(17):2869-78.
    View in: PubMed
  81. Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999 Oct; 6(10):1751-8.
    View in: PubMed
  82. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther. 1999 Sep 1; 10(13):2237-43.
    View in: PubMed
  83. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol. 1999 Aug; 73(8):6319-26.
    View in: PubMed
  84. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999 Jun; 1(2):162-9.
    View in: PubMed
  85. Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999 Apr; 6(4):564-72.
    View in: PubMed
  86. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999 Feb 10; 10(3):385-93.
    View in: PubMed
  87. New KC, Rabkin SD. GABA synthesis in astrocytes after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase 65 or 67. J Neurochem. 1998 Dec; 71(6):2304-12.
    View in: PubMed
  88. Jasmin L, Janni G, Manz HJ, Rabkin SD. Activation of CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation. J Neurosci. 1998 Dec 1; 18(23):10016-29.
    View in: PubMed
  89. New KC, Gale K, Martuza RL, Rabkin SD. Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. Brain Res Mol Brain Res. 1998 Oct 30; 61(1-2):121-35.
    View in: PubMed
  90. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998 Oct 10; 9(15):2177-85.
    View in: PubMed
  91. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998 May 1; 160(9):4457-64.
    View in: PubMed
  92. Rabkin SD, Miyatake S, Martuza RL, inventors. Tumor- or cell-specific herpes simplex virus replication. 1998.
  93. Toda M, Uyemura K, Kawase T, Rabkin SD, Martuza RL. Treatment of metastatic brain tumors with a replication-competent multimutated herpes simplex virus-1. Uyemura K, Kawamura K, Yazaki T. editors. Neural Development. 1998; 521-525.
  94. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 1997 Jul-Aug; 4(4):222-8.
    View in: PubMed
  95. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997 Jul; 71(7):5124-32.
    View in: PubMed
  96. Yazaki T, Martuza RL, Rabkin SD. Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration. Brain Res Mol Brain Res. 1996 Dec 31; 43(1-2):311-20.
    View in: PubMed
  97. Martuza RL, Rabkin SD, Mineta T, inventors. Replication-competent herpes simplex virus mediates destruction of neoplastic cells. 1996.
  98. Rabkin SD, Mineta T, Miyatake S, Yazaki T. Gene therapy: targeting tumor cells for destruction. Hum Cell. 1996 Dec; 9(4):265-76.
    View in: PubMed
  99. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol. 1996 Aug; 50(2):236-42.
    View in: PubMed
  100. New KC, Rabkin SD. Co-expression of two gene products in the CNS using double-cassette defective herpes simplex virus vectors. Brain Res Mol Brain Res. 1996 Apr; 37(1-2):317-23.
    View in: PubMed
  101. Hunter W, Yazaki T, Rabkin S, Martuza R. Replication-competent viral therapy of tumors in the central nervous system. Lowenstein P, Enquist L. editors. Protocols for Gene Transfer in Neuroscience: towards gene therapy of neurological disorders. 1996; 305-317.
  102. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995 Nov 1; 55(21):4752-6.
    View in: PubMed
  103. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995 Sep; 1(9):938-43.
    View in: PubMed
  104. Hunter W, Rabkin S, Martuza R. Brain tumor therapy using genetically engineered replication-competent virus. Kaplitt M, Loewy A. editors. Viral Vectors. 1995; 259-274.
  105. Yazaki T, Takamiya Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RL. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol. 1995; 23(1):23-9.
    View in: PubMed
  106. Wood MJ, Byrnes AP, Kaplitt MG, Pfaff DW, Rabkin SD, Charlton HM. Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting. Exp Neurol. 1994 Nov; 130(1):127-40.
    View in: PubMed
  107. Verhaagen J, Hermens WT, Oestreicher AB, Gispen WH, Rabkin SD, Pfaff DW, Kaplitt MG. Expression of the growth-associated protein B-50/GAP43 via a defective herpes-simplex virus vector results in profound morphological changes in non-neuronal cells. Brain Res Mol Brain Res. 1994 Oct; 26(1-2):26-36.
    View in: PubMed
  108. Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, Pfaff DW. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci U S A. 1994 Sep 13; 91(19):8979-83.
    View in: PubMed
  109. Wood MJ, Byrnes AP, Pfaff DW, Rabkin SD, Charlton HM. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Ther. 1994 Sep; 1(5):283-91.
    View in: PubMed
  110. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994 Aug 1; 54(15):3963-6.
    View in: PubMed
  111. Kaplitt MG, Tjuvajev JG, Leib DA, Berk J, Pettigrew KD, Posner JB, Pfaff DW, Rabkin SD, Blasberg RG. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol. 1994; 19(2):137-47.
    View in: PubMed
  112. Mineta T, Markert JM, Takamiya Y, Coen DM, Rabkin SD, Martuza RL. CNS tumor therapy by attenuated herpes simplex viruses. Gene Ther. 1994; 1 Suppl 1:S78.
    View in: PubMed
  113. New KC, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors for the study of promoter and gene function in the CNS. Gene Ther. 1994; 1 Suppl 1:S79.
    View in: PubMed
  114. Wood MJ, Byrnes AP, Rabkin SD, Pfaff DW, Charlton HM. Immunological consequences of HSV-1-mediated gene transfer into the CNS. Gene Ther. 1994; 1 Suppl 1:S82.
    View in: PubMed
  115. Clarke P, Rabkin SD, Inman MV, Mahalingam R, Cohrs R, Wellish M, Gilden DH. Molecular analysis of simian varicella virus DNA. Virology. 1992 Oct; 190(2):597-605.
    View in: PubMed
  116. Kaplitt, M., Rabkin, S. D. and Pfaff, D. W. Molecular alterations in nerve cells: Direct manipulation and physiological mediation. Curr Top Neuroendocrin. 1992; 11:169-191.
  117. Rabkin SD, Hanlon B. Nucleoprotein complex formed between herpes simplex virus UL9 protein and the origin of DNA replication: inter- and intramolecular interactions. Proc Natl Acad Sci U S A. 1991 Dec 1; 88(23):10946-50.
    View in: PubMed
  118. Kaplitt MG, Pfaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DW. Expression of a functional foreign gene in adult mammalian brain following in Vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol Cell Neurosci. 1991 Aug; 2(4):320-30.
    View in: PubMed
  119. Rabkin SD, Hanlon B. Herpes simplex virus DNA synthesis at a preformed replication fork in vitro. J Virol. 1990 Oct; 64(10):4957-67.
    View in: PubMed
  120. Rabkin SD, Richardson CC. In vivo analysis of the initiation of bacteriophage T7 DNA replication. Virology. 1990 Feb; 174(2):585-92.
    View in: PubMed
  121. Rabkin SD, Richardson CC. Initiation of DNA replication at cloned origins of bacteriophage T7. J Mol Biol. 1988 Dec 20; 204(4):903-16.
    View in: PubMed
  122. Richardson CC, Beauchamp BB, Huber HE, Ikeda RA, Myers JA, Nakai H, Rabkin SD, Tabor S, White J. Bacteriophage T7 DNA replication. McMacken R, Kelly TJ. editors. DNA Replication and Recombination. . 1987; 47:151-171.
  123. Strauss B, Larson K, Rabkin S, Sagher D, Sahm J. Termination of synthesis resulting from modifying bases in DNA. IARC Sci Publ. 1986; (70):387-92.
    View in: PubMed
  124. Strauss B, Larson K, Rabkin S, Sagher D, Sahm J, Shenkar R. In vitro models for mutagenesis: a role for lesion, polymerase and sequence. Prog Clin Biol Res. 1986; 209A:149-59.
    View in: PubMed
  125. Strauss BS, Larson K, Sagher D, Rabkin S, Shenkar R, Sahm J. In vitro models of mutagenesis. Carcinog Compr Surv. 1985; 10:481-93.
    View in: PubMed
  126. Strauss BS, Larson K, Sagher D, Rabkin S, Shenkar R, Sahm J. In vitro models of mutagenesis. Huberman E. editor. The Role of Chemicals and Radiation in the Etiology of Cancer. Carcinogenesis. 1985; 10:481-509.
  127. Rabkin SD, Strauss BS. A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts. J Mol Biol. 1984 Sep 25; 178(3):569-94.
    View in: PubMed
  128. Strauss B, Rabkin S, Sagher D. Interaction of DNA polymerase and adduct conformation in the specificity of incorporation opposite carcinogenic lesions in DNA. Bishop J, Greaves M, Rowley J, editors. Genes and Cancer. . 1984; 17:157-166.
  129. Rabkin SD. In Vitro DNA synthesis on mutagen reacted templates. 1984.
  130. Rabkin SD, Moore PD, Strauss BS. In vitro bypass of UV-induced lesions by Escherichia coli DNA polymerase I: specificity of nucleotide incorporation. Proc Natl Acad Sci U S A. 1983 Mar; 80(6):1541-5.
    View in: PubMed
  131. Strauss B, Ayres K, Bose K, Moore P, Rabkin S, Sklar R, Lindgren V. Molecular alterations in DNA associated with mutation and chromosome rearrangements. German J. editor. Chromosome Breakage and Neoplasia. 1983; 281-315.
  132. Moore PD, Rabkin SD, Osborn AL, King CM, Strauss BS. Effect of acetylated and deacetylated 2-aminofluorene adducts on in vitro DNA synthesis. Proc Natl Acad Sci U S A. 1982 Dec; 79(23):7166-70.
    View in: PubMed
  133. Moore PD, Rabkin SD, Osborn AL, Strauss BS. Interactions between DNA polymerase and aminofluorene adducts that affect the recognition and possibly the mutagenicity of the lesions. Biochimie. 1982 Aug-Sep; 64(8-9):757-62.
    View in: PubMed
  134. Strauss B, Rabkin S, Sagher D, Moore P. The role of DNA polymerase in base substitution mutagenesis on non-instructional templates. Biochimie. 1982 Aug-Sep; 64(8-9):829-38.
    View in: PubMed
  135. Moore PD, Rabkin SD, Strauss BS. In vitro replication of mutagen-damaged DNA: Sites of termination. Lemontt JF, Generoso WM. editors. Molecular and Cellular Mechanisms of Mutagenesis. 1982; 179-197.
  136. Moore PD, Rabkin SD, Strauss BS. In vitro replication of mutagen-damaged DNA: sites of termination. Basic Life Sci. 1982; 20:179-97.
    View in: PubMed
  137. Moore PD, Bose KK, Rabkin SD, Strauss BS. Sites of termination of in vitro DNA synthesis on ultraviolet- and N-acetylaminofluorene-treated phi X174 templates by prokaryotic and eukaryotic DNA polymerases. Proc Natl Acad Sci U S A. 1981 Jan; 78(1):110-4.
    View in: PubMed
  138. Friedman A, Rabkin S, Becker Y. Electron microscopy of branched HSV DNA molecules: Possible recombination intermediates. Becker Y. editor. Herpesvirus DNA. 1981; 85-93.
  139. Rabkin S, Shtram Y, Becker Y. Replication of HSV-1 DNA: Isolation of a subnuclear DNA synthesizing fraction. Becker Y. editor. Herpesvirus DNA. 1981; 95-106.
  140. Rabkin S, Becker Y. Biosynthesis of defective HSV DNA. Becker Y. editor. Herpesvirus DNA. 1981; 185-195.
  141. Moore PD, Rabkin SD, Strauss BS. Termination of vitro DNA synthesis at AAF adducts in the DNA. Nucleic Acids Res. 1980 Oct 10; 8(19):4473-84.
    View in: PubMed
  142. Rabkin SD. Biosynthesis of herpes simplex virus defective and wild-type DNA in vivo and in subnuclear fractions. 1980.
  143. Becker Y, Gutter B, Cohen Y, Chejanovsky N, Rabkin S, Fridlender B. Herpes simplex virus DNA polymerase, thymidine kinase and deoxyribonuclease activities in cells infected with wild type, ultraviolet-irradiated and defective virus. Arch Virol. 1979; 62(3):163-74.
    View in: PubMed
  144. Becker Y, Asher Y, Weinberg-Zahlering E, Rabkin S, Friedmann A, Kessler E. Defective herpes simplex virus DNA: circular and circular-linear molecules resembling rolling circles. J Gen Virol. 1978 Aug; 40(2):319-35.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Rabkin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_